Volume 31, Supplement—December 2025
SUPPLEMENT ISSUE
Supplement
Nonspecific Symptoms Attributable to Lyme Disease in High-Incidence Areas, United States, 2017–2021
Courtney C. Nawrocki, Mark J. Delorey, Austin R. Earley, Sarah A. Hook, Kiersten J. Kugeler, Grace E. Marx, Paul S. Mead, and Alison F. Hinckley
Table 2
Risk for nonspecific symptom codes among case-patients and control-patients in the prediagnosis and postdiagnosis years in study of nonspecific symptoms attributable to Lyme disease in high-incidence areas, United States, 2017–2021
| Measure | Any symptom | Pain | Fatigue | Cognitive difficulties |
|---|---|---|---|---|
| Risk ratio prediagnosis (95% CI) | 1.05 (1.03–1.07) | 1.03 (1.01–1.05) | 1.35 (1.29–1.41) | 0.91 (0.81–1.01) |
| Risk ratio postdiagnosis (95% CI) | 1.12 (1.11–1.14) | 1.10 (1.08–1.12) | 1.67 (1.61–1.72) | 1.18 (1.08–1.28) |
| Ratio of relative risks (95% CI) | 1.07 (1.05–1.10) | 1.07 (1.04–1.10) | 1.24 (1.17–1.30) | 1.30 (1.13–1.49) |
| Attributable risk postdiagnosis, % | 10.9 | 8.7 | 40.2 | 16.1 |
*Symptom codes from the International Classification of Diseases, 10th Revision, Clinical Modification.
Page created: August 27, 2025
Page updated: January 22, 2026
Page reviewed: January 22, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.